MedTrace Logo

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

NCT03433469 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2026-03-30

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well osimertinib works in treating participants with stage I-IIIA Epithelial Growth Factor Receptor (EGFR) -mutant non-small cell lung cancer before surgery. Osimertinib may stop the growth of tumor cells by blocking mutant EGFR signaling in cancer cells.

Conditions

  • Stage I Non-Small Cell Lung Cancer
  • Stage IA Non-Small Cell Lung Cancer
  • Stage IB Non-Small Cell Lung Cancer
  • Stage II Non-Small Cell Lung Cancer
  • Stage IIA Non-Small Cell Lung Cancer
  • Stage IIB Non-Small Cell Lung Cancer
  • Stage IIIA Non-Small Cell Lung Cancer

Interventions

DRUG

Osimertinib

Given PO (orally)

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Sponsors & Collaborators

Principal Investigators

  • Collin Blakely, MD, PhD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-31
Primary Completion
2023-01-31
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03433469 on ClinicalTrials.gov